Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $14.00 by Analysts at Truist Financial

Y-mAbs Therapeutics (NASDAQ:YMAB) had its price target cut by Truist Financial from $18.00 to $14.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

YMAB has been the topic of a number of other research reports. Morgan Stanley cut their price target on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a report on Wednesday, March 5th. HC Wainwright dropped their target price on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating for the company in a report on Friday, March 21st. Oppenheimer cut their target price on Y-mAbs Therapeutics from $21.00 to $20.00 and set an “outperform” rating on the stock in a research note on Wednesday. Wedbush reaffirmed an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. Finally, Bank of America cut Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 price objective for the company. in a report on Tuesday, April 22nd. Two research analysts have rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $16.70.

Y-mAbs Therapeutics Price Performance

YMAB opened at $4.10 on Wednesday. The stock’s 50 day simple moving average is $4.47 and its 200 day simple moving average is $7.11. The firm has a market cap of $185.64 million, a price-to-earnings ratio of -7.59 and a beta of 0.53. Y-mAbs Therapeutics has a 1 year low of $3.55 and a 1 year high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.10. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The firm had revenue of $20.90 million during the quarter, compared to analyst estimates of $19.97 million. As a group, sell-side analysts anticipate that Y-mAbs Therapeutics will post -0.65 EPS for the current year.

Insiders Place Their Bets

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the transaction, the insider now owns 202,721 shares in the company, valued at approximately $1,060,230.83. This represents a 5.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 22.50% of the stock is currently owned by company insiders.

Institutional Trading of Y-mAbs Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Barclays PLC lifted its position in Y-mAbs Therapeutics by 433.4% during the 3rd quarter. Barclays PLC now owns 69,222 shares of the company’s stock valued at $910,000 after acquiring an additional 56,244 shares during the period. Wells Fargo & Company MN grew its holdings in Y-mAbs Therapeutics by 54.1% in the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company’s stock worth $137,000 after purchasing an additional 6,131 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Y-mAbs Therapeutics by 10.4% during the third quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company’s stock valued at $399,000 after purchasing an additional 2,854 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Y-mAbs Therapeutics by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 822,309 shares of the company’s stock valued at $6,440,000 after purchasing an additional 8,820 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Y-mAbs Therapeutics by 1.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 284,540 shares of the company’s stock valued at $2,228,000 after purchasing an additional 4,963 shares during the last quarter. 70.85% of the stock is owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.